Skip to main content
OpenTrials
Completed

NCT Number: NCT05696379

Angiography Derived Index of Microcirculatory Resistance in Patients With Acute Myocardial Infarction

Coronary microcirculatory dysfunction has been known to be prevalent even after successful revascularization of acute myocardial infarction (AMI) patients, and has been shown to be associated with poor prognosis. Angiography derived index of micro-circulatory resistance (Angio-IMR) is a novel pressure-wire free approach to assess coronary microvascular disease with great diagnostic performance. The current study will further investigate the prognostic value of Angio-IMR in patients with AMI in multicenter retrospective cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myocardial Infarction (AMI)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310009, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute myocardial infarction patients who underwent successful percutaneous coronary intervention

Exclusion criteria

  • No appropriate coronary angiography images (inferior image quality, image loss, severe arteries overlap, or significant artifact)
  • Previous coronary artery bypass graft

Treatment and study plan

Angiography derived index of micro-circulatory resistance (Angio-IMR)

Other

Angiography derived index of micro-circulatory resistance (Angio-IMR) post percutaneous coronary intervention.

Primary outcomes

  1. Cardiac death or readmission for heart failure in 1 month

    Time frame: 1 month

    Incidence of cardiac death or readmission for heart failure during first 1 month follow-up.

  2. Cardiac death or readmission for heart failure in 6 months

    Time frame: 6 month

    Incidence of cardiac death or readmission for heart failure during first 6 months follow-up.

  3. Cardiac death or readmission for heart failure in 1 year

    Time frame: 1 year

    Incidence of cardiac death or readmission for heart failure during first 1 year follow-up.

  4. Cardiac death or readmission for heart failure in 2 years

    Time frame: 2 year

    Incidence of cardiac death or readmission for heart failure during first 2 years follow-up.

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Collaborators

  • RenJi Hospital
  • Shengjing Hospital

Registry information

Important dates

Study start
2017
Primary completion
2022
Study completion
2022
First posted
Jan 25, 2023
Registry last updated
Jan 25, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.